- In March 2025, Illumina Inc. launched its next-generation NovaSeq X Plus sequencing platform in key global markets, offering enhanced throughput, reduced sequencing costs, and integrated AI-powered analytics to accelerate whole genome sequencing applications in clinical and research settings
- In February 2025, the UK government announced a major expansion of its Genomics England program, aiming to sequence an additional 1 million genomes over the next five years to advance rare disease diagnosis, cancer research, and personalized healthcare initiatives
- In January 2025, Thermo Fisher Scientific introduced its Ion Torrent Genexus Dx Integrated Sequencer, a fully automated NGS platform designed for clinical diagnostic use, enabling same-day results and simplifying genomic workflows for oncology and infectious disease applications
- In November 2024, BGI Genomics partnered with the Indian Council of Medical Research (ICMR) to establish a nationwide genomic surveillance program targeting antimicrobial resistance and genetic disorders, marking a significant step toward public health preparedness and precision medicine in India
- In October 2024, CRISPR Therapeutics and Vertex Pharmaceuticals received expanded FDA approval for their gene-editing therapy, Casgevy, for treating additional beta-thalassemia genotypes, reinforcing the role of genomics in advanced therapeutic solutions and personalized treatment approaches
